New Modality Oral Biologics Platform For Treatment Of GI Disorders

Fzata's vision :  Reduce health inequities by expanding patient access to therapeutic biologics. 

 

Our oral biologics for gastrointestinal (GI) disorders will:

1. improve patient accessibility to biologics with at home, non-refrigerated, convenient oral capsules

2.  improve patient compliance with no needles and no  health-care administrated infusion

3.  improve chronic use outcomes given the high safety profile, no ADA, no systemic tox.​

​​

The Fzata proprietary oral Bioengineered Probiotic Yeast Medicines (BioPYM) platform empowers orally administered yeast micro-factories to make biologic therapeutics “on-site” in the gut for treatment of GI diseases.  

Utilizing BioPYM, we have a deep preclinical pipeline of oral biologics to treat GI-related disorders.

​

​